"I strongly believe that there will be a totally different way to treat cancer patients in the next 10 years," declared Michael V. Seiden, MD, PhD, shortly after he became president and CEO of Fox Chase Cancer Center in June 2007. "I think tumors will be removed and analyzed in a much more molecularly-based way. This is already being done at the research level, but in 10 years, therapies will be selected for people based on the molecular characterization of their tumors and how those therapies are working will be dissected in a much more sophisticated way, using techniques like molecular imaging."
Fox Chase's leader sets forth a bold challenge--one he thinks Fox Chase is uniquely positioned to meet. Its scientists and physicians conduct basic laboratory, clinical, translational, population and behavioral studies. Combining research in many disciplines with patient care enables Fox Chase to translate new research findings into medical ...
